^
Association details:
| Biomarker: | EML4-ALK fusion + ALK G1202R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) + PF-07284892 (PTPN11 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
Published date:
08/04/2023
Excerpt:
Instead, the patient continued PF-07284892 (at an initial lower dose of 10 mg b.i.w.; Fig. 2E and Methods), and lorlatinib was added [100 mg daily (qd), the dose the patient previously progressed on]....ALK–EML4 and ALK G1202R in ctDNA showed early decreases after 1 week of combination and then all three ctDNA species increased after 3 weeks of combination...The PR was confirmed after 12 weeks of combination therapy (study week 18)...
DOI:
https://doi.org/10.1158/2159-8290.CD-23-0361
